• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [23475 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2024     Health Sciences Institute in Aragon (IACS) Programme for the use of real world data in health technology assessment. Potential uses for real world data in the Spanish HTA Network
2024     NIHR Health Services and Delivery Research programme Factors influencing effective data sharing between health care and social care regarding the care of older people: a qualitative evidence synthesis
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: breast cancer screening with breast tomosynthesis]
2024     NIHR Health Technology Assessment programme Doppler ultrasound surveillance of recently formed haemodialysis arteriovenous fistula: the SONAR observational cohort study
2024     NIHR Health Technology Assessment programme Clinical and cost‐effectiveness of pessary self‐management versus clinic-based care for pelvic organ prolapse in women: the TOPSY RCT with process evaluation
2024     NIHR Health Services and Delivery Research programme Service design for children and young people with common mental health problems: literature review, service mapping and collective case study
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: linezolid plasma dosing]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Methodology report: glossary of terms used in pharmacoeconomics]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: overview of polypharmacy and use of potentially inappropriate medications among people aged 65 and over in Quebec]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Newsletter: genomic medicine in healthcare systems - challenges and opportunities]
2024     NIHR Health Services and Delivery Research programme Linkage of routinely collected NHS data to evaluate liaison mental health services: challenges and lessons learned
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: judicious use of medical biology tests in the diagnosis and treatment of Helicobacter pylori infection]
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Renal denervation
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Alemtuzumab, cladribine, fingolimod, and natalizumab as first-line treatments in adult patients with highly active relapsing multiple sclerosis
2024     NIHR Health Technology Assessment programme Advice only versus advice and a physiotherapy programme for acute traumatic anterior shoulder dislocation: the ARTISAN RCT
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: delirium in elderly persons in emergency departments - prevention, assessment and management]
2024     NIHR Health Services and Delivery Research programme Evaluation of different models of general practitioners working in or alongside emergency departments: a mixed-methods realist evaluation
2024     Penn Medicine Center for Evidence-based Practice (CEP) Patient hand hygiene before meals for infection control
2024     NIHR Health Technology Assessment programme Establishing a research partnership to investigate functional loss and rehabilitation towards the end of life
2024     Penn Medicine Center for Evidence-based Practice (CEP) Renal denervation for treatment of resistant hypertension
2024     NIHR Health Services and Delivery Research programme Causes and solutions to workplace psychological ill-health for nurses, midwives and paramedics: the Care Under Pressure 2 realist review
2024     The Danish Health Technology Council (DHTC) [Assessment of domiciliary non-invasive ventilation for patients with chronic obstructive pulmonary disease]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: equivalence of the positivity threshold of immunochemical fecal occult blood tests for colorectal cancer screening]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Portable automated sputum suction]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Patient specific aortic graft guidance for open thoracoabdominal aortic repair]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Migraine surgery]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Endorectal cooling accompanying prostate cancer surgery]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Endoscopic anti-reflux mucosectomy, ARMS]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Resuscitative endovascular balloon occlusion of the aorta]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Algorithm-based Alzheimer's disease diagnosis-aided test using plasma biomarkers]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Irreversible electroporation for renal cancer]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Real time high resolution MR image guidance during irradiation]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Gastrointestinal bleeding control using endoscopic hemostatic powder]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Monocyte distribution width, MDW]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Artificial intelligence-based screening test for emergent large vessel occlusion using non-contrast brain CT images]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Artificial intelligence-based diagnostic assistant test for paroxysmal atrial fibrillation using 12-lead electrocardiogram data]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Less invasive surfactant administration]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Magnetic resonance imaging-guided transurethral ultrasound ablation of localized prostate cancer]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Magnetic resonance imaging-guided transurethral ultrasound ablation of prostatic hyperplasia]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Emotional freedom technique]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Radiofrequency catheter ablation using in-silico modelling in atrial fibrillation]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Endograft fixation]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Laparoscopic and endoscopic cooperative surgery for gastrointestinal tumor]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Artificial intelligence-based diagnostic assistant test for acute myocardial infarction using 12-lead electrocardiogram data]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Markerless real-time monitoring surface guided radiation therapy]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Seoul Cognitive Status Test]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Autologous platelet rich fibrin therapy to promote wound healing]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [von Willebrand Factor collagen binding activity [high quality immunoassay]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Intraoperative CT imaging system for navigational spine surgery]
2024     NIHR Health and Social Care Delivery Program Relationship between staff and quality of care in care homes: StaRQ mixed methods study
2024     NIHR Health Technology Assessment programme Bisphosphonate alternative regimens for the prevention of osteoporotic fragility fractures: BLAST-OFF, a mixed-methods study
2024     NIHR Health Technology Assessment programme Evaluation of venous thromboembolism risk assessment models for hospital inpatients: the VTEAM evidence synthesis
2024     HTA Region Stockholm [Comparing coronary computed tomography angiography (CCTA) to exercise electrocardiogram for suspected coronary artery disease: impact on patient outcomes]
2024     HTA Region Stockholm [Effectiveness of intravesical instillation for overactive bladder including bladder pain syndrome]
2024     National Institute for Health and Care Excellence (NICE) Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer. NICE technology appraisal guidance 944
2024     National Institute for Health and Care Excellence (NICE) Treosulfan with fludarabine before allogeneic stem cell transplant for people aged 1 month to 17 years with non-malignant diseases (terminated appraisal). NICE technology appraisal guidance 945
2024     National Institute for Health and Care Excellence (NICE) Olaparib with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer. NICE technology appraisal guidance 946
2024     National Institute for Health and Care Excellence (NICE) Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments. NICE technology appraisal guidance 947
2024     National Institute for Health and Care Excellence (NICE) Ivosidenib for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatments. NICE technology appraisal guidance 948
2024     National Institute for Health and Care Excellence (NICE) Belumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and over. NICE technology appraisal guidance 949
2024     National Institute for Health and Care Excellence (NICE) Nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over. NICE technology appraisal guidance 950
2024     National Institute for Health and Care Excellence (NICE) Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer. NICE technology appraisal guidance 951
2024     National Institute for Health and Care Excellence (NICE) Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations. NICE technology appraisal guidance 952
2024     National Institute for Health and Care Excellence (NICE) Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema. NICE technology appraisal guidance 953
2024     National Institute for Health and Care Excellence (NICE) Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments. NICE technology appraisal guidance 954
2024     National Institute for Health and Care Excellence (NICE) Dupilumab for treating moderate to severe prurigo nodularis. NICE technology appraisal guidance 955
2024     National Institute for Health and Care Excellence (NICE) Etrasimod for treating moderately to severely active ulcerative colitis in people aged 16 and over. NICE technology appraisal guidance 956
2024     National Institute for Health and Care Excellence (NICE) Momelotinib for treating myelofibrosis-related splenomegaly or symptoms. NICE technology appraisal guidance 957
2024     National Institute for Health and Care Excellence (NICE) Ritlecitinib for treating severe alopecia areata in people 12 years and over. NICE technology appraisal guidance 958
2024     National Institute for Health and Care Excellence (NICE) Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis. NICE technology appraisal guidance 959
2024     National Institute for Health and Care Excellence (NICE) Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders (terminated appraisal). NICE technology appraisal guidance 960
2024     National Institute for Health and Care Excellence (NICE) Sebelipase alfa for treating lysosomal acid lipase deficiency that is not Wolman disease (terminated appraisal). NICE technology appraisal guidance 961
2024     National Institute for Health and Care Excellence (NICE) Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy. NICE technology appraisal guidance 962
2024     National Institute for Health and Care Excellence (NICE) Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency. NICE technology appraisal guidance 963
2024     National Institute for Health and Care Excellence (NICE) Cabozantinib with nivolumab for untreated advanced renal cell carcinoma. NICE technology appraisal guidance 964
2024     National Institute for Health and Care Excellence (NICE) Human alpha1-proteinase inhibitor for treating emphysema (terminated appraisal). NICE technology appraisal guidance 965
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: initiating an HPV test and following up on results for cervical cancer screening]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: relevance of preoperative consultation and testing for low-risk elective surgery in people aged 16 and over]
2024     Health Information and Quality Authority (HIQA) Health technology assessment of birth cohort testing for hepatitis C: a short report update
2024     Health Information and Quality Authority (HIQA) Review of national rare disease strategies in selected countries
2024     Center for Outcomes Research and Economic Evaluation for Health (C2H) [Cost-effectiveness evaluation of molnupiravir (Lagevrio)]
2024     Center for Outcomes Research and Economic Evaluation for Health (C2H) [Cost-effectiveness evaluation of finerenone (Kerendia)]
2024     Health Technology Wales (HTW) Liposuction for the treatment of chronic lymphoedema
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Decision aid for hip joint replacement]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Avapritinib (indolent systemic mastocytosis) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (melanoma, adjuvant, stage IIB or IIC) – Addendum to Project A23-94]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pegunigalsidase alfa (Fabry disease) – Addendum to Project A23-95]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Palopegteriparatide (chronic hypoparathyroidism) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (biliary cancer) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (gastric cancer, HER2-negative) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (gastric or gastro-oesophageal junction adenocarcinoma, HER2-positive) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dostarlimab (endometrial cancer) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Empagliflozin (type 2 diabetes mellitus in children and adolescents) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Polatuzumab vedotin (combination with rituximab, cyclophosphamide, doxorubicin and prednisone for DLBCL – Benefit assessment according to § 35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Polatuzumab vedotin (relapsed or refractory DLBCL) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Letermovir (CMV prophylaxis after stem cell transplantation) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Durvalumab (HCC) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Letermovir (CMV prophylaxis after kidney transplant) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Alirocumab (hypercholesterolaemia) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lanadelumab (hereditary angioedema, 2 to < 12 years) – Benefit assessment according to §35a Social Code Book V]